Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide

Inclusion Criteria

• •Patients with chronic HDV-related hepatitis or compensated liver cirrhosis (Child-Pugh class A)
• •Positive HDV RNA within the 24 weeks prior to enrollment
• •Ongoing antiviral therapy for HBV at the time of enrollment
• •First prescription of Bulevirtide 2 mg issued within 30 days prior to enrollment
• •Caucasian ethnicity
• •Age ≥18 years
• •Normocaloric omnivorous diet
• •No intake of antibiotics, probiotics, or prebiotics in the month prior to enrollment
• •Signed informed consent